SRZN on Nasdaq

Surrozen, Inc./DE

American biological products company based in South San Francisco.

$24.85 up 1.10 (4.63%)Price as of Oct 15, 2026 at 17:33 UTC

Last updated Oct 18, 2026.

Overview

Compare with CRISPR Therapeutics, DYADIC INTERNATIONAL INC or CG Oncology, Inc., or pick any stock.

TickerSRZN on Nasdaq
IndustryBiological Products, (No Diagnostic Substances)
HeadquartersDE
Incorporated inDE³
Business address171 Oyster Point Blvd, Suite 400, South San Francisco, Ca 94080³
Filer categoryNon-accelerated filer, Smaller reporting company³

See how the biggest companies compare on our leaderboards

Financials

From the company’s reports to the SEC. Every number links to the filing it came from.

Key numbers, fiscal 2025

-1210.6%Operating margin⁴

-6960.8%Net margin⁴

-67.4%Revenue growth, 2025⁴

-$30.4MFree cash flow⁴

Where the money goes

Where each dollar of revenue went, fiscal 2025

Research and development

Research and development100¢$29.4M

Out of $3.5M in revenue.⁴ The company lost money this year.

Financial statements

Revenue⁵⁶⁷⁴$3.5M in 2025

Operating income⁸⁵⁶⁷⁴-$42.1M in 2025+28% since 2020

Net income⁸⁵⁶⁷⁴-$242.0M in 2025+640% since 2020

Every line of the income statement as filed: the last 2 fiscal years, latest first.⁴

Period ending	2025-12-31	2024-12-31
Revenue	$3.5M	$10.7M
Total Revenue	$3.5M	$10.7M
Research and development	$29.4M	$21.1M
General and administrative	$16.2M	$15.1M
Total operating expenses	$45.6M	$36.2M
Loss from operations	-$42.1M	-$25.5M
Interest income	$3.0M	$1.7M
Loss on issuance of common stock, pre-funded warrants and warrants in the 2024 PIPE	$0	-$20.4M
Loss on amendment and cancellation of warrants	-$2.1M	$0
Loss on execution of the 2025 PIPE	-$71.1M	$0
Loss on change in fair value of tranche liability	-$104.8M	$0
Gain on settlement of tranche liability	$1.4M	$0
Other expense, net	-$26.3M	-$19.3M
Net loss and comprehensive loss	-$242.0M	-$63.6M
Net loss per share attributable to common stockholders, basic	-$32.37	-$21.67
Net loss per share attributable to common Stockholders, diluted	-$32.37	-$21.67
Weighted-average shares used in computing net loss per share attributable to common stockholders, basic	7.5K shares	2.9K shares
Weighted-average shares used in computing net loss per share attributable to common stockholders, diluted	7.5K shares	2.9K shares

Total assets⁸⁵⁶⁷⁴$98.7M in 2025+59% since 2020

Total liabilities⁸⁵⁶⁷⁴$286.5M in 2025+1840% since 2020

Shareholders’ equity⁸⁵⁶⁷⁴-$187.8M in 2025

Cash⁸⁵⁶⁷⁴$89.2M in 2025+202% since 2019

Every line of the balance sheet as filed: the last 3 fiscal years (annual) or 3 quarters (quarterly), latest first.⁴

Period ending	2025-12-31	2024-12-31	2023-12-31
Cash and cash equivalents	$89.2M	$34.6M
Accounts receivable	$0	$2.0M
Accounts receivable - related party	$208.0K	$502.0K
Prepaid expenses and other current assets	$2.1M	$1.8M
Total current assets	$91.6M	$38.9M
Property and equipment, net	$433.0K	$562.0K
Operating lease right-of-use assets	$6.0M	$7.8M
Restricted cash	$688.0K	$688.0K
Warrant asset	$0	$153.0K
Other assets	$46.0K	$331.0K
Total assets	$98.7M	$48.5M
Accounts payable	$728.0K	$306.0K
Accrued and other liabilities	$7.9M	$5.2M
Lease liabilities, current portion	$1.3M	$1.8M
Total current liabilities	$9.9M	$7.3M
Lease liabilities, noncurrent portion	$5.3M	$6.6M
Tranche liability	$158.7M	$0
Warrant liabilities	$112.5M	$55.9M
Total liabilities	$286.5M	$69.8M
Preferred stock, $0.0001 par value, 10,000 shares authorized; no shares issued and outstanding as of December 31, 2025 and 2024	$0	$0
Common stock, $0.0001 par value, 500,000 shares authorized as of December 31, 2025 and 2024; 9,775 and 3,262 shares issued and outstanding as of December 31, 2025 and 2024, respectively	$1.0K	$0
Additional paid-in-capital	$339.5M	$263.9M
Accumulated deficit	-$527.3M	-$285.3M
Total stockholders' deficit	-$187.8M	-$21.4M	$37.9M
Total liabilities and stockholders' deficit	$98.7M	$48.5M
Preferred stock, par value	$0.00	$0.00
Preferred stock, shares authorized	10.0M shares	10.0M shares
Preferred stock, shares issued	0 shares	0 shares
Preferred stock, shares outstanding	0 shares	0 shares
Common shares, par value	$0.00	$0.00
Common shares, shares authorized	500.0M shares	500.0M shares
Common stock shares issued	9.8M shares	3.3M shares
Common shares, shares outstanding	9.8M shares	3.3M shares

Period ending	2025-12-31	2024-12-31	2023-12-31
Cash and cash equivalents	$89.2M	$34.6M
Accounts receivable	$0	$2.0M
Accounts receivable - related party	$208.0K	$502.0K
Prepaid expenses and other current assets	$2.1M	$1.8M
Total current assets	$91.6M	$38.9M
Property and equipment, net	$433.0K	$562.0K
Operating lease right-of-use assets	$6.0M	$7.8M
Restricted cash	$688.0K	$688.0K
Warrant asset	$0	$153.0K
Other assets	$46.0K	$331.0K
Total assets	$98.7M	$48.5M
Accounts payable	$728.0K	$306.0K
Accrued and other liabilities	$7.9M	$5.2M
Lease liabilities, current portion	$1.3M	$1.8M
Total current liabilities	$9.9M	$7.3M
Lease liabilities, noncurrent portion	$5.3M	$6.6M
Tranche liability	$158.7M	$0
Warrant liabilities	$112.5M	$55.9M
Total liabilities	$286.5M	$69.8M
Preferred stock, $0.0001 par value, 10,000 shares authorized; no shares issued and outstanding as of December 31, 2025 and 2024	$0	$0
Common stock, $0.0001 par value, 500,000 shares authorized as of December 31, 2025 and 2024; 9,775 and 3,262 shares issued and outstanding as of December 31, 2025 and 2024, respectively	$1.0K	$0
Additional paid-in-capital	$339.5M	$263.9M
Accumulated deficit	-$527.3M	-$285.3M
Total stockholders' deficit	-$187.8M	-$21.4M	$37.9M
Total liabilities and stockholders' deficit	$98.7M	$48.5M
Preferred stock, par value	$0.00	$0.00
Preferred stock, shares authorized	10.0M shares	10.0M shares
Preferred stock, shares issued	0 shares	0 shares
Preferred stock, shares outstanding	0 shares	0 shares
Common shares, par value	$0.00	$0.00
Common shares, shares authorized	500.0M shares	500.0M shares
Common stock shares issued	9.8M shares	3.3M shares
Common shares, shares outstanding	9.8M shares	3.3M shares

Cash from operations⁸⁵⁶⁷⁴-$30.2M in 2025+4% since 2020

Capital spending⁸⁵⁶⁷⁴$128.0K in 2025−85% since 2020

Free cash flow⁸⁵⁶⁷⁴-$30.4M in 2025+1% since 2020

Share buybacks⁵⁶$0 in 2023

Every line of the cash flow as filed: the last 2 fiscal years, latest first.⁴

Period ending	2025-12-31	2024-12-31
Net loss	-$242.0M	-$63.6M
Depreciation and amortization	$537.0K	$1.4M
Stock-based compensation	$3.8M	$4.1M
Non-cash operating lease expense	$1.8M	$1.5M
Loss on execution of the 2025 PIPE	$71.1M	$0
Loss on issuance of common stock, pre-funded warrants and warrants in the 2024 PIPE	$0	$20.4M
Transaction costs allocated to pre-funded warrants and warrants in connection with the 2025 PIPE and 2024 PIPE	$2.8M	$1.5M
Change in fair value of tranche liability	$104.8M	$0
Change in fair value of warrant liabilities	$22.8M	$17.8M
Loss on amendment and cancellation of warrants	$2.1M	$0
Gain on settlement of tranche liability	-$1.4M	$0
Loss on foreign currency remeasurement	$0	$113.0K
Non-cash consideration received in connection with research service revenue	-$769.0K	-$153.0K
Non-cash impairment of warrant asset	$922.0K	$0
Accounts receivable	$2.0M	$0
Accounts receivable -related party	$294.0K	-$502.0K
Prepaid expenses and other current assets	-$67.0K	$1.1M
Other assets	$72.0K	$71.0K
Accounts payable	$142.0K	-$228.0K
Accrued and other liabilities	$2.5M	$1.1M
Operating lease liabilities	-$1.8M	-$2.3M
Net cash used in operating activities	-$30.2M	-$17.6M
Purchases of property and equipment	-$128.0K	-$26.0K
Net cash (used in) provided by investing activities	-$128.0K	-$26.0K
Proceeds from issuance of common stock	$74.7M	$16.0M
Proceeds from issuance of common stock under the ATM program, net of transaction costs	$9.1M	$0
Proceeds from issuance of common stock upon exercise of warrants	$987.0K	$0
Proceeds from issuance of common stock upon employee stock plan purchases	$198.0K	$94.0K
Proceeds from issuance of common stock upon exercise of stock options	$87.0K	$39.0K
Net cash provided by financing activities	$85.1M	$16.2M
Net (decrease) increase in cash, cash equivalents and restricted cash	$54.7M	-$1.5M
Increase in right-of-use assets and lease liabilities due to a lease modification	$0	$7.4M
Transaction costs for the 2025 PIPE included in accrued and other liabilities	$229.0K	$0
Purchases of equipment included in accounts payable	$280.0K	$9.0K
Vesting of early exercises of stock options	$0	$2.0K

Compare Surrozen, Inc./DE with another company

Leadership

Who has led Surrozen, Inc./DE, and when. Pick a name to see everywhere that person has worked.

Chief executive

Craig C. Parker2021–now

Chief financial officer

2025

Chief executive officerCraig C. Parker Aug 16, 2021 to now¹¹
Chief financial officerAndrew Pedrum Maleki Nov 13, 2025 to now¹²
Chief financial officerKevin Harold Livingston Nov 18, 2020 to May 19, 2021¹³

Board members and other officers (18)

Chief Medical OfficerGeertrui Vanhove Aug 16, 2021 to Dec 19, 2022¹⁴
Chief Scientific OfficerWen-Chen Yeh Aug 16, 2021 to Jun 20, 2023¹⁵
VP Business DevelopmentJoshua Cory House Nov 18, 2020 to Nov 18, 2020¹⁶
Board memberEric Bjerkholt Apr 5, 2023 to now¹⁷
Board memberLife Sciences Consonance May 19, 2021 to May 19, 2021¹⁸
Board memberAnna Berkenblit Aug 16, 2021 to now¹⁹
Board memberChristopher Y. Chai Aug 16, 2021 to now²⁰
Board memberCraig C. Parker Aug 16, 2021 to now¹¹
Board memberDavid J. Woodhouse Aug 16, 2021 to now²¹
Board memberMary Haak-Frendscho Aug 16, 2021 to now²²
Board memberShao-Lee Lin Aug 16, 2021 to now²³
Board memberTim Kutzkey Aug 16, 2021 to now²⁴
Board memberBenny Soffer Nov 18, 2020 to May 19, 2021²⁵
Board memberChristopher Haqq Nov 18, 2020 to Nov 18, 2020²⁶
Board memberDonald J. Santel Nov 18, 2020 to Nov 18, 2020²⁷
Board memberGad Soffer Nov 18, 2020 to Nov 18, 2020²⁸
Board memberJennifer Jarrett Nov 18, 2020 to Nov 18, 2020²⁹
Board memberMitchell J. Blutt Md. Nov 18, 2020 to May 19, 2021³⁰

Former names

Consonance-HFW Acquisition Corp.Sep 18, 2020 to Aug 11, 2021³

Timeline

Aug 16, 2021New chief executive Craig C. Parker becomes CEO¹¹

Filings

353 filings to the SEC since October 2021: 5 annual reports, 15 quarterly reports, 48 major events, 128 insider forms, 63 large holders, 2 private raises, 92 other. The latest 20:

Oct 7, 2026SCHEDULE 13G/A EDGAR
Oct 2, 20268-K EDGAR
Oct 1, 2026SCHEDULE 13G EDGAR
Aug 14, 2026SCHEDULE 13G/A EDGAR
Aug 14, 2026SCHEDULE 13G EDGAR
Aug 14, 2026SCHEDULE 13G/A EDGAR
Aug 11, 2026SCHEDULE 13G/A EDGAR
Aug 7, 202625-NSE EDGAR
Aug 6, 202610-Q EDGAR
Aug 6, 20268-K EDGAR
Jul 24, 2026SCHEDULE 13G/A EDGAR
Jul 24, 20264 EDGAR
Jun 16, 20264 EDGAR
Jun 16, 20264 EDGAR
Jun 16, 20264 EDGAR
Jun 16, 20264 EDGAR
May 19, 20264 EDGAR
May 18, 2026SCHEDULE 13D/A EDGAR
May 15, 2026SCHEDULE 13G/A EDGAR
May 15, 2026SCHEDULE 13G/A EDGAR

The 353 filings since October 2021 can be filtered by form type and year here when JavaScript is on.

Every filing from the last three years, summarized. The full record is on SEC EDGAR.

Insider trades and holders

Large holders

Investors who own more than 5% must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively. 63 such filings since October 2021, the latest 10:

From Forms 4 and Schedules 13D and 13G filed with the SEC.

Money raised

Private offerings the company reported to the SEC on Form D.

Mar 26, 2025Raised $76.4 million in a private offering of equity Form D: $175 million offered in all Form D
Apr 4, 2024Raised $193 million in a private offering of equity Form D: 18 investors so far Form D

Held by these funds

The largest holders among investment managers' 13F reports for the quarter ending Jun 30, 2026, the top 25 of 69. Change is in shares since the quarter before.

Fund	Shares	Value	Share of the fund	Change
TCG Crossover Management, LLC	1,473,101	$38.2M	0.9%	No change
Boxer Capital Management, LLC	1,105,683	$27.0M	2.0%	+339,365
Kalehua Capital Management LLC	770,356	$20.0M	6.4%	No change
Millennium Management LLC	683,079	$17.7M	0.0%	−48,059
Point72 Asset Management, L.P.	664,272	$17.2M	0.0%	New
Venrock Adviser, LLC	632,931	$16.4M	0.5%	No change
Stempoint Capital LP	602,798	$13.8M	2.4%	−118,822
Perceptive Advisors LLC	503,985	$13.1M	0.2%	+274,592
Spruce Street Capital LP	432,040	$11.2M	2.2%	No change
BlackRock, Inc.	394,864	$10.2M	0.0%	+367,013
Vanguard Capital Management LLC	392,550	$10.2M	0.0%	+223,458
Braidwell LP	390,753	$10.1M	0.4%	−5,347
Vestal Point Capital, LP	304,669	$7.9M	0.2%	−33,942
5AM Venture Management, LLC	271,250	$7.0M	2.4%	−116,250
Vivo Capital, LLC	260,000	$6.7M	0.6%	No change
Balyasny Asset Management L.P.	205,032	$5.3M	0.0%	+1,144
Geode Capital Management, LLC	201,652	$5.2M	0.0%	+135,803
Acuta Capital Partners, LLC	173,395	$4.5M	3.1%	+548
Regents Of The University Of California	133,207	$3.5M	0.1%	No change
State Street Corp	133,084	$3.5M	0.0%	+105,358
Goldman Sachs Group Inc	113,531	$2.9M	0.0%	+87,680
Adage Capital Partners Gp, L.l.c.	88,653	$2.3M	0.0%	No change
Euclidean Capital LLC	87,696	$2.3M	0.5%	No change
Two Sigma Investments, LP	71,119	$1.8M	0.0%	+31,637
Northern Trust Corp	63,609	$1.7M	0.0%	+51,344

13F reports cover disclosed long positions in U.S. stocks only.

Sources

The numbers on this page point here. Each one links to the record it came from.

1
SEC EDGARSurrozen, Inc./DE filings on SEC EDGAR
2
Yahoo FinanceSRZN quote
3
SEC EDGARSurrozen, Inc./DE filings on SEC EDGAR
4
SEC EDGARSurrozen, Inc./DE 10-K for fiscal 2025
5
SEC EDGARSurrozen, Inc./DE 10-K for fiscal 2021
6
SEC EDGARSurrozen, Inc./DE 10-K for fiscal 2022
7
SEC EDGARSurrozen, Inc./DE 10-K for fiscal 2023
8
SEC EDGARSurrozen, Inc./DE 10-K for fiscal 2020
9
SEC EDGARSurrozen, Inc./DE 10-Q for fiscal 2026
10
SEC EDGARSurrozen, Inc./DE 10-Q for fiscal 2026
11
SEC EDGARCraig C. Parker, Chief executive officer
12
SEC EDGARAndrew Pedrum Maleki, Chief financial officer
13
SEC EDGARKevin Harold Livingston, Chief financial officer
14
SEC EDGARGeertrui Vanhove, Chief Medical Officer
15
SEC EDGARWen-Chen Yeh, Chief Scientific Officer
16
SEC EDGARJoshua Cory House, VP Business Development
17
SEC EDGAREric Bjerkholt, Board member
18
SEC EDGARLife Sciences Consonance, Board member
19
SEC EDGARAnna Berkenblit, Board member
20
SEC EDGARChristopher Y. Chai, Board member
21
SEC EDGARDavid J. Woodhouse, Board member
22
SEC EDGARMary Haak-Frendscho, Board member
23
SEC EDGARShao-Lee Lin, Board member
24
SEC EDGARTim Kutzkey, Board member
25
SEC EDGARBenny Soffer, Board member
26
SEC EDGARChristopher Haqq, Board member
27
SEC EDGARDonald J. Santel, Board member
28
SEC EDGARGad Soffer, Board member
29
SEC EDGARJennifer Jarrett, Board member
30
SEC EDGARMitchell J. Blutt Md., Board member